BioCentury | Dec 17, 2020
Emerging Company Profile

Exo: expanding the universe of druggable enzymes

...against non-catalytic, non-allosteric sites.Exo Therapeutic Inc., which is backed by Newpath Partners, Novartis Venture Fund, CRV...
...focus: Inflammation, cancerClinical status: PreclinicalFounded: 2018 by David Liu, Alan Saghatelian, Juan Pablo Maianti, Newpath, CRV...
...DimensionsUniversity collaborators: N/ACorporate partners: N/ANumber of employees: 9Funds raised: $25 millionInvestors: Newpath, Novartis Venture Fund, CRV...
BioCentury | Oct 14, 2020
Deals

Roche deal sets up capsid developer Dyno for faster growth, push into more therapeutic areas

...seed funding co-led by Polaris Partners and CRV...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...Ventures and Catalio Capital Management. Also participating were LS Polaris Innovation Fund, Arch Venture Partners, CRV...
...Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, LS Polaris Innovation Fund, Arch Venture Partners, CRV...
BioCentury | May 11, 2020
Emerging Company Profile

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

...in gene therapy.” The company has raised a lone seed round from Polaris Partners and CRV...
...AG, Sarepta Therapeutics Inc. Number of employees: 20 Funds raised: $9 million Investors: Polaris Partners, CRV...
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...Two Sigma Ventures, Obvious Ventures, Felicis Ventures, Epic Ventures, Menlo Ventures, AME Cloud Ventures and CRV...
BioCentury | Sep 14, 2018
Financial News

Neurological organoid company System1 raises $25M in series A

...Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV...
...University of California San Francisco assistant professor Saul Kato co-founded System1. Escola serves as CEO. CRV's...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro , cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in vitro...
BioCentury | Oct 13, 2017
Finance

Repurposing Recursion

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...
BioCentury | Oct 10, 2017
Company News

Recursion, Takeda enter rare disease discovery partnership

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
Items per page:
1 - 10 of 13
BioCentury | Dec 17, 2020
Emerging Company Profile

Exo: expanding the universe of druggable enzymes

...against non-catalytic, non-allosteric sites.Exo Therapeutic Inc., which is backed by Newpath Partners, Novartis Venture Fund, CRV...
...focus: Inflammation, cancerClinical status: PreclinicalFounded: 2018 by David Liu, Alan Saghatelian, Juan Pablo Maianti, Newpath, CRV...
...DimensionsUniversity collaborators: N/ACorporate partners: N/ANumber of employees: 9Funds raised: $25 millionInvestors: Newpath, Novartis Venture Fund, CRV...
BioCentury | Oct 14, 2020
Deals

Roche deal sets up capsid developer Dyno for faster growth, push into more therapeutic areas

...seed funding co-led by Polaris Partners and CRV...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...Ventures and Catalio Capital Management. Also participating were LS Polaris Innovation Fund, Arch Venture Partners, CRV...
...Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, LS Polaris Innovation Fund, Arch Venture Partners, CRV...
BioCentury | May 11, 2020
Emerging Company Profile

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

...in gene therapy.” The company has raised a lone seed round from Polaris Partners and CRV...
...AG, Sarepta Therapeutics Inc. Number of employees: 20 Funds raised: $9 million Investors: Polaris Partners, CRV...
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...Two Sigma Ventures, Obvious Ventures, Felicis Ventures, Epic Ventures, Menlo Ventures, AME Cloud Ventures and CRV...
BioCentury | Sep 14, 2018
Financial News

Neurological organoid company System1 raises $25M in series A

...Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV...
...University of California San Francisco assistant professor Saul Kato co-founded System1. Escola serves as CEO. CRV's...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro , cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in vitro...
BioCentury | Oct 13, 2017
Finance

Repurposing Recursion

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...
BioCentury | Oct 10, 2017
Company News

Recursion, Takeda enter rare disease discovery partnership

...Epic Ventures, AME Cloud Ventures, Advantage Capital and Felicix, and new investors Mubadala, Menlo Ventures, CRV...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
Items per page:
1 - 10 of 13